John M Vierling

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Future Treatment Options in PBC
    John M Vierling
    Baylor Liver Health, Baylor College of Medicine, Houston, TX 77030, USA
    Semin Liver Dis 25:347-63. 2005
  2. ncbi request reprint Etiopathogenesis of primary sclerosing cholangitis
    Christine A O'Mahony
    Department of Surgery, Baylor Liver Health, Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 26:3-21. 2006
  3. doi request reprint Diagnosis and treatment of autoimmune hepatitis
    John M Vierling
    Liver Center, Baylor College of Medicine, St Luke s Episcopal Hospital, Houston, TX 77030, USA
    Curr Gastroenterol Rep 14:25-36. 2012
  4. doi request reprint Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    John M Vierling
    Baylor College of Medicine, Houston, TX, United States Electronic address
    J Hepatol 60:748-56. 2014
  5. pmc The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease
    John M Vierling
    Trans Am Clin Climatol Assoc 122:326-35. 2011
  6. ncbi request reprint The immunology of hepatitis B
    John M Vierling
    Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA
    Clin Liver Dis 11:727-59, vii-viii. 2007
  7. pmc Low rates of hepatitis B virus screening at the onset of chemotherapy
    Jessica P Hwang
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Oncol Pract 8:e32-9. 2012
  8. pmc Hepatitis B virus management to prevent reactivation after chemotherapy: a review
    Jessica P Hwang
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Support Care Cancer 20:2999-3008. 2012
  9. pmc Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
    Jessica P Hwang
    Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1465, Houston, Texas 77030, USA
    BMC Cancer 13:534. 2013
  10. doi request reprint An overview of emerging therapies for the treatment of chronic hepatitis C
    Jawad A Ilyas
    Liver Center, St Luke s Episcopal Hospital, Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA Department of Medicine, Baylor College of Medicine, 1709 Dryden Street, Suite 500, Houston, TX 77030, USA Department of Surgery, Baylor College of Medicine, 1709 Dryden Street, Suite 1500, Houston, TX 77030, USA
    Med Clin North Am 98:17-38. 2014

Detail Information

Publications25

  1. ncbi request reprint Future Treatment Options in PBC
    John M Vierling
    Baylor Liver Health, Baylor College of Medicine, Houston, TX 77030, USA
    Semin Liver Dis 25:347-63. 2005
    ..Induction of tolerance in susceptible people before onset of disease or of hyporesponsiveness in established disease is increasingly feasible, as is prevention of biliary fibrosis...
  2. ncbi request reprint Etiopathogenesis of primary sclerosing cholangitis
    Christine A O'Mahony
    Department of Surgery, Baylor Liver Health, Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 26:3-21. 2006
    ..Progressive periductal fibrosis, chronic inflammation, and ischemic atrophy of biliary epithelia result in ductopenia, cholestasis, and obstructive strictures, culminating in secondary biliary cirrhosis...
  3. doi request reprint Diagnosis and treatment of autoimmune hepatitis
    John M Vierling
    Liver Center, Baylor College of Medicine, St Luke s Episcopal Hospital, Houston, TX 77030, USA
    Curr Gastroenterol Rep 14:25-36. 2012
    ....
  4. doi request reprint Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    John M Vierling
    Baylor College of Medicine, Houston, TX, United States Electronic address
    J Hepatol 60:748-56. 2014
    ..We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin...
  5. pmc The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease
    John M Vierling
    Trans Am Clin Climatol Assoc 122:326-35. 2011
    ....
  6. ncbi request reprint The immunology of hepatitis B
    John M Vierling
    Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA
    Clin Liver Dis 11:727-59, vii-viii. 2007
    ..Replicative intermediates can persist in the liver under immunologic control after resolution of acute or chronic hepatitis B, conferring a risk for reactivation following a course of immunosuppression or chemotherapy...
  7. pmc Low rates of hepatitis B virus screening at the onset of chemotherapy
    Jessica P Hwang
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Oncol Pract 8:e32-9. 2012
    ..Previous studies have shown low screening rates, but no large-scale US studies have been conducted. We sought to determine predictors of screening and positive HBV test results in patients receiving chemotherapy...
  8. pmc Hepatitis B virus management to prevent reactivation after chemotherapy: a review
    Jessica P Hwang
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Support Care Cancer 20:2999-3008. 2012
    ..Conflicting recommendations regarding HBV screening in cancer patients awaiting chemotherapy mean that some patients at risk for HBV reactivation are not being identified and treated with prophylactic antiviral therapy...
  9. pmc Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
    Jessica P Hwang
    Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1465, Houston, Texas 77030, USA
    BMC Cancer 13:534. 2013
    ..We aimed to determine contemporary screening rates at a cancer center and the possible influence on these rates of publication of national recommendations...
  10. doi request reprint An overview of emerging therapies for the treatment of chronic hepatitis C
    Jawad A Ilyas
    Liver Center, St Luke s Episcopal Hospital, Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA Department of Medicine, Baylor College of Medicine, 1709 Dryden Street, Suite 500, Houston, TX 77030, USA Department of Surgery, Baylor College of Medicine, 1709 Dryden Street, Suite 1500, Houston, TX 77030, USA
    Med Clin North Am 98:17-38. 2014
    ..Patients with CHC should continue to consider participation in clinical trials of new therapies to accelerate progress...
  11. doi request reprint Liver transplantation in autoimmune liver diseases
    Jawad A Ilyas
    Fellow in Hepatology and Liver Transplantation, Liver Center, Baylor College of Medicine and St Luke s Episcopal Hospital, 1709 Dryden, Suite 1500, Houston, TX 77030, USA
    Best Pract Res Clin Gastroenterol 25:765-82. 2011
    ..Better understanding of the pathogenesis of recurrent autoimmune liver diseases is needed to devise effective means of prevention and treatment...
  12. doi request reprint Hepatitis C virus viral assays in the direct-acting antiviral era
    John M Vierling
    Department of Medicine, Liver Center, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Liver Dis 17:27-45. 2013
    ..Only quantitative HCV RNA assays with a limit of detection of 10 to 15 IU/mL are appropriate for managing patients on DAA therapy...
  13. doi request reprint Acute liver failure
    N Thao T Nguyen
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Organ Transplant 16:289-96. 2011
    ..The purpose of this review is to summarize the advances in clinical research in ALF during 2009-2010 that are pertinent to hepatologists and transplant surgeons caring for these critically ill patients...
  14. ncbi request reprint Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocation
    Neal R Barshes
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA
    J Contemp Health Law Policy 23:200-30. 2007
  15. pmc Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening
    Jessica P Hwang
    Department of General Internal Medicine at University of Texas M D Anderson Cancer Center, Houston, USA
    Am J Public Health 100:S118-24. 2010
    ..We sought to identify cross-sectional hepatitis B virus (HBV) and HCV prevalence among Asian Americans at a community health fair and to assess referral rates...
  16. doi request reprint Interaction of CD44 and hyaluronic acid enhances biliary epithelial proliferation in cholestatic livers
    Yao He
    Comprehensive Transplant Center, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Am J Physiol Gastrointest Liver Physiol 295:G305-12. 2008
    ..CD44-hyaluronan interaction, by enhancing biliary proliferation, may play a pathogenic role in the development of cholestatic liver diseases...
  17. ncbi request reprint The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host
    Marius Braun
    Center for Liver Diseases and Transplantation and Burns and Allen Research Institute, Cedars Sinai Medical Center, and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Liver Transpl 9:S79-89. 2003
    ..8. After new, less toxic, and more potent antiviral agents become available, they should be tested immediately in patients with hepatitis C post-liver transplantation...
  18. ncbi request reprint Primary biliary cirrhosis and autoimmune cholangiopathy
    John M Vierling
    Center for Liver Diseases and Transplantation, Los Angeles, CA 90048, USA
    Clin Liver Dis 8:177-94. 2004
    ....
  19. pmc Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury
    Junquan Xu
    Liver Center and Department of Medicine, University of California, San Francisco 94110, USA
    Am J Physiol Gastrointest Liver Physiol 287:G734-41. 2004
    ....
  20. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  21. pmc Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients
    M Eric Gershwin
    Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA 95616, USA
    Hepatology 42:1194-202. 2005
    ..Exogenous estrogens may also contribute to explain the female predominance of the disease...
  22. ncbi request reprint T cell immunity and graft-versus-host disease (GVHD)
    Yasunori Ichiki
    Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, TB192, One Shields Avenue, Davis, CA 95616, USA
    Autoimmun Rev 5:1-9. 2006
    ..Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation...
  23. ncbi request reprint Management of patients with cirrhosis in Southern California: results of a practitioner survey
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA
    J Clin Gastroenterol 40:156-61. 2006
    ..A paucity of data exists on how patients with cirrhosis are managed. Our aims were to determine how cirrhosis is managed and whether current management practices follow established recommendations...
  24. pmc Quality of life and everyday activities in patients with primary biliary cirrhosis
    Carlo Selmi
    Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, CA 95616, USA
    Hepatology 46:1836-43. 2007
    ..Nevertheless, patients with PBC suffer significantly more than controls from a variety of symptoms that are beyond the immediate impact of liver failure and affect their lifestyle, personal relationships, and work activities...
  25. ncbi request reprint Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy
    Robert J Fontana
    Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Gastroenterology 123:719-27. 2002
    ....